"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
There is no known treatment to reverse the antiplatelet effect of ZONTIVITY, and neither dialysis nor platelet transfusion can be expected to be beneficial if bleeding occurs after overdose. Inhibition of platelet aggregation can be expected for weeks after discontinuation of normal dosing [see CLINICAL PHARMACOLOGY]. There is no standard test available to assess the risk of bleeding in an overdose situation.
History Of Stroke, Transient Ischemic Attack (TIA), Or Intracranial Hemorrhage (ICH)
Active Pathologic Bleeding
Last reviewed on RxList: 5/28/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Zontivity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.